Last reviewed · How we verify
NCT05447091: THRIVE
Examining the Effectiveness of a Tablet Video Game on Mood and Cognition
NA trial testing LOH game- high dose in Mood Disturbance in 180 participants. Completed in 30 June 2023.
30 June 2023
Quick facts
| Lead sponsor | Hebrew University of Jerusalem |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 180 |
| Start date | 12 June 2022 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- LOH game- high dose
- LOH game- low dose
- LOH sham game
Conditions studied
- Mood Disturbance — all drugs for Mood Disturbance →
- Depressive Symptoms — all drugs for Depressive Symptoms →
Sponsor
Hebrew University of Jerusalem
Who can join
Adults 18 to 60, any sex, with Mood Disturbance or Depressive Symptoms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sustained negative mood and depression are characterized by functional impairment, and significant reduction in quality of life. Cognitive models of depression emphasize the role of impaired cognitive control - the mental abilities determining goal directed behaviors - in contributing to depressive symptoms. Indeed, research findings from subclinical and clinical populations show that depressive symptoms are associated with decreased cognitive control abilities. The THRIVE trial is a double-blind, proof-of-concept randomized controlled trial (RCT). The aims of the study are to investigate the feasibility and efficacy of an innovative, custom-made tablet video game, Legends of Hoa'manu (LOH), which is designed to enhance cognitive control, in alleviating mood and improving cognitive control in adults. Participants with mild to major depressive symptoms will be randomized to receive either LoH or a control intervention. Cognitive control, mood and depressive symptoms will be assessed at baseline, post training, after at a 3-week and a 3-month follow up.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A remotely-applied, cognitive control-based video game intervention to reduce depressive symptoms in a sub-clinical population: A randomized controlled trial (RCT).
Givon Schacham N, Pasqualotto A, Lerner N, Fanourakis M, et al · · 2026 · PMID 41187581 · DOI 10.1016/j.comppsych.2025.152645
Verify or expand the search:
- PubMed search for NCT05447091
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mood Disturbance
Currently open trials in the same condition.
- NCT06531863 — Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance · EARLY_PHASE1 · recruiting
- NCT06054412 — An Adjunctive Neurofeedback Training Program to Enhance Wellness Among Trauma-Exposed Postpartum Mothers · NA · active not recruiting
Other Hebrew University of Jerusalem trials
Trials by the same sponsor.
- NCT07003282 — A Study to Test Feasibility and Acceptability of an Intervention Program Aiming to Reduce Prenatal Secondhand Smoke Expo · NA · recruiting
- NCT05771545 — Telepsychiatry to Enable Expedited Disposition of Psychiatric Emergencies · active not recruiting
- NCT04697316 — Transcranial Direct Current Stimulation (tDCS) as a Cognitive Functioning Enhancement Treatment for ADHD Patients Compar · NA · completed
- NCT07025603 — Evaluation of the Social ABCs in Israel · NA · completed
- NCT04376918 — Bag-Valve-Guedel Adaptor Vs Common Face Mask for the Ventilation of Anesthetized Bearded Men · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05447091 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hebrew University of Jerusalem
- Last refreshed: 21 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05447091.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing